AstraZeneca and Forest Laboratories, Inc. announced today that ceftazidime/avibactam (CAZ-AVI) will enter phase III trials to investigate efficacy in treating hospitalised patients with serious Gram-negative bacterial infections including Complicated Intra-Abdominal Infections (cIAI) and Complicated Urinary Tract Infections (cUTI). CAZ-AVI combines a broad-spectrum cephalosporin (ceftazidime) and a novel beta-lactamase inhibitor (avibactam, formerly NXL104) to overcome antibiotic-resistance and treat the increasing number of infections resistant to existing therapies.

TxCell SA, a biotechnology company developing Treg cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high unmet medical needs, announces today the presentation of final positive results of the phase I/II study in Crohn’s disease (CATS-1) with its leading product candidate, OvaSave(R). The results of this study, performed on 20 patients, were announced at the United European Gastroenterology Week (UEGW) in Stockholm, held October 22 to 26.

First results from a large-scale Phase III trial of RTS,S, published online today in the New England Journal of Medicine (NEJM), show the malaria vaccine candidate to provide young African children with significant protection against clinical and severe malaria with an acceptable safety and tolerability profile. The results were announced today at the Malaria Forum hosted by the Bill & Melinda Gates Foundation in Seattle, Washington.

More Articles ...

Subscribe to our Newsletter
Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok